Monitor FDA review of the sBLA for full approval, expected in mid-2027, and the pace of TRUTAKNA patient starts and revenue ramp in Q4 2026 and Q1 2027. The European MAA submission planned for Q1 2027 is a secondary catalyst.
Drug in focus
VERA drug pipeline →TRUTAKNA
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
- Next catalyst
- None dated
What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.
Price Chart
Executive Summary
Vera Therapeutics reported Q3 2026 net product revenue of $10.3 million from the TRUTAKNA launch, its first revenue quarter, with approximately 700 Patient Start Forms received. Net loss widened to $93.7 million ($1.30 per share) from $80.3 million ($1.26 per share) a year ago, driven by $61.4 million in SG&A expenses for the commercial launch. The company completed its sBLA submission for full FDA approval of TRUTAKNA, with a decision expected in mid-2027.
Key Financial Metrics
Key Facts
- First-ever product revenue of $10.3 million from TRUTAKNA launch in Q3 2026
- Approximately 700 Patient Start Forms received since accelerated approval on July 7, 2026
- Completed sBLA submission to FDA on November 3, 2026 for full approval of TRUTAKNA
- ORIGIN 3 final efficacy analysis showed stabilization of kidney function and 76% reduction in risk of composite kidney disease progression
- Net loss of $93.7 million ($1.30 per share) vs $80.3 million ($1.26 per share) in Q3 2025
- Cash, cash equivalents and marketable securities of $384 million as of September 30, 2026; pro forma $459 million including $75 million drawn in late October
- Up to $350 million remains available under debt facility
Financial Impact
First product revenue of $10.3 million in Q3 2026; net loss of $93.7 million; cash position of $384 million ($459 million pro forma)
Risk Factors
- Full FDA approval is contingent on sBLA review and may not be granted
- Commercial launch is early; revenue trajectory and payer coverage remain unproven at scale
- Net loss and cash burn are increasing as SG&A spending ramps for the launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449780 |
| Document: vera-20261105.htm | 0001193125-26-449780 |
| Document: 0001193125-26-449780-index-headers.html | 0001193125-26-449780 |
| Document: 0001193125-26-449780-index.html | 0001193125-26-449780 |
| Document: 0001193125-26-449780.txt | 0001193125-26-449780 |
| 8-K Data (Synthetic) | 0001193125-26-449780 |
Track record
25 reports on VERA
13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers